Background: Medical cannabis use is an emerging topic of interest in orthopedics. Although there is a large amount of literature on medical cannabis use for managing various types of pain, few studies have focused on orthopedic conditions. There is little high-quality evidence in core orthopedic areas. The objective of this study was to summarize the literature on the efficacy of cannabis use for pain related to orthopedic conditions.
M edical cannabis is an emerging topic of interest in the field of orthopedics. Given the recent focus on the dangers of opioids 1,2 and the trend toward legalizing medical and recreational cannabis use in Canada and some American states, 3 there is a need for safe strategies to manage pain in orthopedic conditions. Osteoarthritis pain affects 27 million people in the United States, 4 back pain affects one-quarter of Americans 5 and up to 40% of the pain of patients with chronic pain originated from trauma or surgery. 6 The pain of patients with orthopedic conditions can be complicated and difficult to treat because it can be chronic and/or acute, nociceptive, inflammatory and/or neuropathic. As populations age internationally, there is concern that the burden of pain related to orthopedic conditions will increase 7 and therefore there will be an increased need for alternative and adjuvant strategies to manage pain associated with orthopedic conditions. Medical cannabis use has been hypothesized as a possible solution both to help control pain and to reduce opioid use.
There has been a considerable amount of research on medical cannabis use, particularly for the management of pain. A systematic review of cannabis use for any indication concluded that cannabis is a promising medication for pain as well as several other conditions/symptoms. 8 For example, a controlled clinical trial found that vapourized cannabis improves neuropathic pain, 9 and several studies have investigated the role of cannabis in fibromyalgia 10 and spasticity caused by multiple sclerosis. 11 Additionally, cannabis use may play a role in reducing opioid, alcohol and illicit drug use among patients with pain. 12 There is also some preliminary evidence that medical cannabis use can help patients with pain related to orthopedic conditions. Blake and colleagues 13 found that the pain of patients with rheumatoid arthritis was significantly improved when they used cannabis, and the authors identified the need for further investigation in this area.
Despite a large body of evidence, previous studies have not been able to identify the optimal type of cannabis, dosage, route and frequency of administration. Previous systematic reviews on medical cannabis use have not focused on orthopedic conditions. A recent scoping review on medical cannabis use for the management of musculoskeletal pain identified a need for further high-quality studies in 4 key orthopedic areas: arthritis, back pain, postsurgical pain and posttrauma pain. 14 The objective of this study was to summarize the literature on the efficacy of cannabis use for pain related to orthopedic conditions. We focused on the efficacy of cannabis use in the context of the methodologies used in the published cannabis literature. We further identified which protocols of cannabis administration (e.g., dose, route, frequency, type), comparators and outcomes are commonly used.
Methods
We conducted a systematic review of the available literature on the use of cannabinoids for pain management in core orthopedic conditions (posttrauma pain, postsurgery pain, back pain and arthritis) as part of a large scoping review. 14 
Literature search
On the basis of previous systematic reviews in the field, we developed a systematic search strategy of the MEDLINE, Embase, PsycINFO and Cochrane databases using keywords related to cannabis, marijuana or related cannabinoid terms AND pain search terms on May 1, 2017. We used medical subject heading (MeSH) terms wherever possible. We did not use any language or date limits. Full search strategies for each database were previously reported. 14 We used the Ovid search interface and RefWorks software to manage the references.
Study eligibility
Using DistillerSR systematic review management software (evidencepartners.com), 2 reviewers (K.M., A.G., N.J.V., F.M.B.) independently reviewed each title and abstract for eligibility. Disagreements resulted in inclusion in the next stage. At the full-text stage, 2 reviewers independently reviewed full-text papers and disagreements were resolved by discussion and consultation with a senior author (M.B.) if necessary. Inclusion criteria included the following: (a) primary clinical research in humans (i.e., not animal or basic science studies or nonsystematic reviews), (b) treatment with a cannabis-based medication (i.e., a medication containing or derived from tetrahydrocannabinol [THC] and/or cannabidiol [CBD]), (c) conducted in a therapeutic context (i.e., not recreational) regarding pain management and (d) not exclusively about cancer pain. We did not have any restrictions on study design other than the fact that Conclusion : En raison de la variabilité des méthodologies utilisées dans la recherche sur le cannabis, il est difficile de tirer des conclusions sur la posologie, les voies et la fréquence d'administration. La plupart des preuves disponibles donnent à penser que le cannabis médical est efficace, mais cette efficacité n'a été démontrée que s'il n'y avait pas de comparateur ou si le cannabis était comparé à un placebo. Les études ayant utilisé un comparateur actif n'ont pas fait état d'efficacité. La recherche future devrait veiller à améliorer les rapports et la qualité méthodologique des études afin de déterminer quels protocoles améliorent la maîtrise de la douleur tout en réduisant les effets négatifs.
we excluded nonsystematic reviews. At the final stage, we excluded all studies that were not related to 1 of 4 core orthopedic topics: (a) posttrauma pain, (b) postsurgical pain, (c) back pain and (d) arthritis.
Data extraction
We used DistillerSR software to design a study-specific data extraction form. We extracted reporting quality; risk of bias/methodologic quality; drug name, dose, route and frequency, the population; control; duration of study; pain outcomes; and the authors' conclusions on efficacy relating to pain.
Reporting quality
Wherever possible, we selected well-used reporting quality tools for each study type included in this review, which are endorsed by the Enhancing the Quality and Transparency of Research (EQUATOR) network (equator-network.org). The EQUATOR network is an international organization dedicated to improving the reporting quality of health research by developing and promoting the use of reporting guidelines. For randomized controlled trials (RCTs), we used the Consolidated Standards of Reporting Trials (CONSORT) checklist; 15 for cohort studies, we used Strengthening the Reporting of Observational Studies in Epidemiology (STROBE); 16 for systematic reviews, we used Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA); 17 for qualitative studies, we used Standards of Reporting for Qualitative Research (SRQR); 18 and for case series and case reports, we used the Case Report (CARE) checklist. 19 Surveys do not have a well-established reporting guideline, so we used the "Good practice in the conduct and reporting of survey research" list developed by Kelley and colleagues. 20 We scored each item on the checklists as adequately reported, not reported or not applicable. For example, some trials did not have binary outcomes, so they were exempt from reporting both absolute and relative effects and were scored as not applicable. We did not count items that were not applicable in the denominator when calculating the percentage of adequately reported items.
Risk of bias and methodologic quality
We used the Cochrane Risk of Bias tool 21 and the Cochrane Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool 22 to assess the methodologic quality of randomized trials and observational studies, respectively. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines to assess the credibility of systematic reviews and meta-analyses. 23 
Statistical analysis
All data are presented descriptively as means and standard deviations where possible for continuous data and as frequencies and percentages for categorical data. We could not perform a meta-analysis because of differences in the drugs, doses, routes, frequencies, populations, comparison drugs and outcomes used across studies. Instead, for studies that had a comparsion group, we summarized study conclusions for pain outcomes as (a) cannabis performed better than comparator for pain outcomes, (b) cannabis performed worse than comparator for pain outcomes or (c) no difference on pain outcomes. For noncontrolled studies such as case series and surveys, we categorized studies on the basis of the authors' conclusions as (a) cannabis performed well in a noncontrolled study, (b) cannabis did not perform well in a noncontrolled study or (c) inconclusive or mixed results in a noncontrolled study.
Results
After removal of duplicates we reviewed 7759 potentially eligible studies, of which 118 studies assessed cannabis use for treatment of general musculoskeletal pain. We included 33 core orthopedic studies in the current review, but we focused on 21 primary studies because the 12 systematic reviews included mostly overlapping studies. The full study flow diagram is shown in Figure 1 .
Reporting quality
Reporting quality was relatively low to moderate for all study designs ( Table 1 ). The mean percentage of correctly reported items was 69% for RCTs, 65% for observational studies and 65% for systematic reviews (means exclude studies that were abstracts only). Some individual studies performed well on the reporting tools; 5 studies scored 80% or higher, 24-28 including 1 study that scored 100%. 26 However, 6 studies scored 50% or lower (excluding abstracts). 13, [29] [30] [31] [32] [33] 
Methodologic quality
The methodologic quality of the included RCTs was mostly unclear, particularly for sequence generation, allocation concealment and blinding outcome assessors. We rated 3 studies as being at high risk of bias for "other bias" owing to potential conflicts of interest. 13, 34, 35 One RCT achieved a low risk of bias rating on all domains. 24 Most observational studies were rated as being at high risk of bias for confounding, selection and measurement bias. We also identified selective outcome reporting bias in 5 studies. 30, [36] [37] [38] [39] No observational studies achieved a low risk of bias rating in each domain. Most systematic reviews were rated as very low (2 studies 32, 40 ) or low quality (5 studies 32,41-44 ). Three systematic reviews achieved a J can chir, 2019 GRADE rating of moderate quality, [45] [46] [47] but none were considered high quality. We were unable to assess the GRADE quality of 2 systematic reviews 48, 49 because only abstracts were available. Most reasons for downgrading the quality were because of risk of bias, indirectness and inconsistency ( Table 2, Table 3 , Table 4 ).
Study design
Of the 33 included studies, 5 were RCTs, 13, 24, 34, 35, 50 1 was a nonrandomized intervention study, 29 8 were case reports/ case series, 30,31,36-39,51,52 6 were surveys, 25-28,53,54 1 was a qualitative study 54 and 12 were systematic reviews. 32, 33, 40, [41] [42] [43] [44] [45] [46] [47] [48] [49] Of the 12 systematic reviews, 9 included RCTs, 32,41-47,49 2 included nonrandomized studies 33, 40 and 1 review 48 was unclear on the design of the included studies.
Population
The 6 controlled intervention studies 13, 24, 29, 34, 35, 50 (5 RCTs and 1 nonrandomized intervention study) included a total of 681 patients. Of these patients, 171 (25.1%) underwent directly orthopedic-related procedures, although in 1 study 50 it was unclear what type of surgery 81 patients underwent. Four of the 6 studies evaluated cannabis use for acute postsurgical pain, 24,29,34,50 1 evaluated patients with rheumatoid arthritis 13 and 1 evaluated chronic neuropathic pain, 35 including 25 orthopedic patients ( Table 5 ).
The 15 noncontrolled studies included 4629 patients. Of these patients, at least 2552 (55.1%) underwent directly orthopedic-related procedures (the numbers were unclear for 4 studies 26,28,,37,53 ). (Table 6 ). 
Outcomes measured
The 6 controlled intervention studies used 6 methods to measure pain outcomes: a numeric rating scale (NRS), a verbal rating scale (VRS), a visual analogue scale (VAS), the sum of pain intensity differences (SPID), the McGill pain questionnaire and the amount of rescue analgesia required ( Table 5 ).
The noncontrolled study used 7 methods to measure pain outcomes: the McGill pain questionnaire, patientcontrolled analgesia (PCA) morphine required, perceived effectiveness, the brief pain inventory (BPI), the treatment outcomes of pain survey (TOPS), a VAS and a qualitative interview asking about pain. In 1 study 38 the method used to measure the pain outcome was unspecified and in 3 studies 25, 26, 28 there were no pain outcomes ( Table 6) .
Efficacy -controlled studies
There were only 6 controlled studies, including 5 RCTs and a nonrandomized intervention study ( Table 5 ). Three studies evaluated the efficacy of nabilone, 24, 34, 35 an oral synthetic cannabinoid. One study evaluated levonantradol, 50 another synthetic cannabinoid that can be administered orally or intramuscularly. One study evaluated nabiximols 13 (trade name Sativex), which is an oral cannabis extract spray that delivers a set dosage of THC and CBD per spray. The nonrandomized study 29 evaluated an oral capsule containing cannabis extract (trade name Cannador).
Oral nabilone
Beaulieu, 34 Frank and colleagues 35 and Levin and colleagues 24 conducted RCTs to evaluate nabilone. These 3 studies included 477 patients who underwent surgery or who had chronic neuropathic pain, only 90 of whom were orthopedic patients. One study was a dose-escalation study evaluating doses of 250 µg to 2 mg and the other 2 studies evaluated 0.5 mg, 1 mg and 2 mg doses. All studies used oral capsules. The frequency of administration also varied greatly between the 3 studies, with 1 study only administering nabilone once, 1 study administering the drug once daily and 1 study administering the drug 3 times daily. One study used a placebo comparator, 1 study used an active comparator (dihydrocodeine) and 1 study had a placebo arm and an active comparator arm (ketoprofen). The studies were generally short in duration, ranging from 300 minutes to 14 weeks. All 3 studies had a pain outcome, using 2 different pain rating scales (VAS pain and NRS pain). None of the 3 studies showed a significant improvement in pain symptoms. In the 2 studies with active comparators, cannabis performed worse than the active comparator in terms of pain relief. Additionally, nabilone had more side effects than dihydrocodeine and a similar number of side effects compared with ketoprofen.
Nabiximols oral spray
One study 13 evaluated nabiximols as an oral spray. Participants started with 1 spray per day before bed and were allowed to increase this to 6 sprays as tolerated. Sprays delivered 2.7 mg THC and 2.5 mg CBD each. Participants used a mean of 14.6 mg THC and 13.5 mg CBD per day by the end of the study period. This study comprised 58 patients with rheumatoid arthritis whose regular medication was not adquately controlling their pain. The study used a placebo as a comparator. The study duration was 5 weeks. Nabiximols use showed an improvement in pain control on the McGill pain score and NRS pain compared with placebo, and there were fewer dropouts from the nabiximols group because of adverse events than from the placebo group.
Oral and intramuscular levonantradol
One study 50 evaluated the use of levonantradol as intramuscular injections. Patients who had undergone surgery (n = 61) were randomly assigned to receive 1-time doses of 1 of 3 strengths of intramuscular levonantradol (0.25 mg, 0.5 mg or 1.0 mg) or placebo. It is unclear how many of these patients underwent orthopedic surgery. The 0.25 mg dose of levonantradol performed similarly to placebo, but the higher doses had analgesic effects. The authors warned that there may have been adverse effects on the central nervous system, although they were mild.
The authors also stated that 20 patients were given 1.5 to 3.0 mg of oral levonantradol but only preliminary results of this investigation were reported.
Oral cannabis extract
One study 29 evaluated an oral cannabis extract in capsule form. This was a nonrandomized dose-escalation study evaluating 1-time administration of 5 mg, 10 mg or 15 mg of cannabis. This study included 65 patients who had undergone surgery, 23 of whom had undergone orthopedic surgical procedures. Although the study only evaluated the effect of cannabis over 6 hours, higher doses reduced pain significantly better than low doses on the basis of the amount of rescue analgesia needed and scores on VRS pain scales.
Efficacy -noncontrolled studies
Fifteen studies were noncontrolled. These studies did not specify a predefined dose, route frequency or study drug ( Table 6 ). As such, the characteristics of the cannabis medications varied greatly. Seven studies did not specify the type of cannabis used. 27, 28, 30, [52] [53] [54] [55] Five studies investigated herbal cannabis or extracts, 26,31,37-39 1 studied dronabinol, 51 1 studied nabilone 36 and 1 study 25 had a mix of dronabinol, nabilone, nabiximols, vapourized THC and herbal cannabis. Most of the studies had various or unspecified doses and frequencies of administration. Routes of administration also varied greatly and included oral capsules, edibles, tinctures, oral spray, inhaled (both smoked and vapourized) and topical. Eight studies were cross-sectional and the remaining 7 studies had durations of 4 days to 8.3 years.
Of the 8 case series/case reports, 7 concluded that cannabis use reduced patients' pain from baseline. 30, [36] [37] [38] [39] 51, 52 The remaining study 31 found that sublingual cannabis use did not significantly reduce patients' pain from baseline. Results of 3 of the 6 included surveys indicated that patients were satisfied with cannabis use as a means of reducing their pain. 27, 53, 54 Pain outcomes were not reported for the remaining 3 surveys. 25, 26, 28 The qualitative study found that patients were satisfied with using cannabis to treat their pain. 54 Results from previous systematic reviews can be found in Appendix 1 (available at canjsurg.ca/001018-a1). Table 7 shows a summary of study conclusions by route of administration and dose, for all studies where a specific route and dose could be identified. This table shows a lack of comparisons with an active comparator. Only nabilone oral capsules were compared with an active comparator, and all studies showed that cannabis performed worse than the active comparator. Conclusions were generally positive (5/7 positive conclusions for oral capsules). Generally, higher doses performed better than lower doses. Three doses of intramuscular levonantradol were identified, with higher doses performing better than lower doses. Smoked cannabis was only evaluated in noncomparative studies, but the conclusions of these studies were positive. Although oral spray was only evaluated in 1 study, the conclusions were also positive. Sublingual oil was also only evaluated in 1 noncomparative study, with mixed results.
Route of administration and dose

discussion
This systematic review of medical cannabis use for the management of pain in orthopedic conditions assessed the efficacy of medical cannabis use with a particular focus on study methodology. Although it appears on the surface that there is a large body of medical cannabis literature, we found that there is a paucity of literature focusing on orthopedic conditions like arthritis pain, postsurgical pain, posttrauma pain and back pain. One concern is that although most of the existing evidence suggests that medical cannabis use is effective, this efficacy has only been demonstrated when either there is no comparator or cannabis is compared with placebo. Studies using an active comparator do not demonstrate efficacy. We have identified a need for improved reporting of study methodology and methodologic quality. Many of the studies included in our review were noncomparative and were therefore limited in terms of the evidence that they could provide for the efficacy of medical cannabis. Most comparative studies included a small number of patients, an even smaller number of whom were orthopedic patients (25% of patients in comparative studies and 55% of patients in noncomparative studies had conditions that were directly orthopedic related). Despite these limitations in the current body of evidence, the overall results provide preliminary evidence that cannabinoids are effective as an intervention for pain management and justify the need for future larger studies in the area. A large degree of heterogeneity is present in the literature because of differences in the drugs, doses, routes, frequencies, populations, comparison drugs and outcomes across studies. As a result, we were unable conduct a metaanalysis and provide a single estimate of the pooled results. However, we are able to provide some qualitative evidence that higher doses of cannabis, in general, had better analgesic properties than lower doses. Oral capsules are the most well-studied route of administration. They typically performed well when compared with placebo, but they performed worse than active comparators. More information is needed from comparisions of cannabis with standard medications as well as from studies using cannabis as an adjunct to standard pain medications.
In this systematic review we did not focus on the harmful effects of cannabis use, although we acknowledge that 
None
Cross-sectional Patientreported (qualitative) (+) BPI = brief pain inventory; MSK = musculoskeletal; NR = not reported; PCA = patient-controlled analgesia; THC= tetrahydrocannabinol; TOPS = treatment outcomes of pain survey; VAS = visual analogue scale. *(+) = cannabis performed significantly better than comparator for pain outcomes; (=) = no difference for pain outcomes. †Abstract only. ‡This study technically had a control group; however, we included it with the noncontrolled studies because it assessed only the demographic characteristics of cannabis users versus nonusers; there was no comparison of pain outcomes across groups. benefits must be studied alongside harms in clinical trials. A previous systematic review focusing on the harmful effects of cannabis use found that 96.6% of the harmful effects of cannabis use are not serious, and there is no evidence that serious adverse events are more common among patients given cannabis than among patients in control groups (rate ratio 1.04, 95% confidence interval 0.79-1.39). 40 However, most studies followed patients for only a short time. 40 The most common nonserious harmful effects included neurologic disorders, gastrointestinal disorders and administration-site conditions. 40 Any future studies should attempt to find an administration protocol that maximizes benefit and minimizes harm. Wang and colleagues 40 found that many studies did not fully report harms, so this should be a priority for future research.
The strengths of this scoping review include the fact that we conducted an exhaustive literature search in duplicate, using several medical databases. Additionally, we were able to include a broad range of study designs. We also included all published abstracts where a full-text article was not available. These strengths also lead to a key limitation: we were unable to conduct a meta-analysis because of heterogeneity, so we present a qualitative summary of study conclusions with a particular focus on methodology (e.g., study design, comparator, dosage, route of administration). This summary gives readers a comprehensive overview of the available literature on the topic.
More studies focusing on orthopedic patients are required to assess the efficacy of cannabinoids in pain management. Further large, high-quality studies are needed as there have been few controlled studies in this population. International collaboration on large, high-quality studies will contribute to the generalizability of study results and will improve researchers' ability to recruit large numbers of patients. Most of the studies included in our study were of short duration; more long-duration studies are needed to assess efficacy in chronic conditions like arthritis. Most studies used a placebo or no comparator rather than an active comparator. Future studies could include an active comparator arm if the aim is to demonstrate the efficacy of cannabis compared with standard medications. The next steps for research in this field should include identifying the optimal dosing and methods of administration of cannabis, evaluating the cost-effectiveness of cannabis relative to other pain treatments, evaluating the efficacy of cannabis compared with and in conjunction with standard pain medications and assessing patients' preferences regarding medical cannabis use.
conclusion
There is minimal high-quality evidence for the efficacy of medical cannabis in pain management within the core orthopedic areas of arthritis pain, postsurgical pain, back pain and posttrauma pain. Although most of the existing evidence suggests that medical cannabis use is effective, this efficacy has only been demonstrated when either there is no comparator or cannabis is compared with placebo. Studies using an active comparator have not demonstrated the efficacy of cannabis use. Additionally, more studies are required to determine factors such as optimal dosing and method of administration. Variability in the methodologies of cannabis research makes it difficult to gain insights about dosing, routes and frequency of administration. Future research should improve reporting and methodologic quality so that protocols that optimize pain control while minimizing harmful effects can be determined. * (++) = cannabis performed significantly better than comparator for pain outcomes; (+) = cannabis performed well in a noncontrolled study; (=) = inconclusive or no difference on pain outcomes; (==) inconclusive or mixed results in a noncontrolled study; (-) = cannabis performed worse than comparator for pain outcomes; (--) = cannabis did not perform well in a noncontrolled study.
